Linked Life Data

1591059

Source:http://linkedlifedata.com/resource/pubmed/id/1591059

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2-3
pubmed:dateCreated
1992-6-26
pubmed:abstractText
21 patients with advanced malignant melanoma were treated with interferon alpha 2a at 9MU daily with vindesine every 21 days. No patient had received previous chemotherapy. The overall response rate was 24% with a median survival time of 33 months in 18 patients. The four complete remissions were maintained for 20, 18, 15 and 11 months, while the single partial remission continues at 18 months after the start of treatment. Side-effects were generally mild or moderate and did not lead to cessation of therapy. This combination provides an active outpatient regimen for advanced melanoma and produces durable remissions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
438-41
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma.
pubmed:affiliation
Department of Medicine, Royal Liverpool Hospital, U.K.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't